Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Maravai LifeSciences Holdings Inc’s stock clocked out at $2.06, down -2.83% from its previous closing price of $2.12. In other words, the price has decreased by -$2.83 from its previous closing price. On the day, 3.36 million shares were traded.
Ratios:
To gain a deeper understanding of MRVI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.17 and its Current Ratio is at 5.96. In the meantime, Its Debt-to-Equity ratio is 1.09 whereas as Long-Term Debt/Eq ratio is at 1.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on February 26, 2025, Downgraded its rating to Neutral and sets its target price to $3 from $9 previously.
Goldman Downgraded its Neutral to Sell on December 05, 2024, while the target price for the stock was maintained at $4.25.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 31 ’25 when ORESHACK KURT sold 25,000 shares for $5.03 per share. The transaction valued at 125,750 led to the insider holds 167,618 shares of the business.
ORESHACK KURT bought 25,000 shares of MRVI for $125,750 on Jan 31 ’25. On Nov 12 ’24, another insider, DeFord John A, who serves as the Director of the company, bought 17,500 shares for $5.75 each. As a result, the insider paid 100,625 and bolstered with 70,046 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.17 while its Price-to-Book (P/B) ratio in mrq is 0.99.
Stock Price History:
Over the past 52 weeks, MRVI has reached a high of $11.56, while it has fallen to a 52-week low of $1.66. The 50-Day Moving Average of the stock is -6.23%, while the 200-Day Moving Average is calculated to be -63.06%.
Shares Statistics:
A total of 143.96M shares are outstanding, with a floating share count of 117.02M. Insiders hold about 18.71% of the company’s shares, while institutions hold 77.24% stake in the company.
Earnings Estimates
Its stock is currently analyzed by 14.0 different market analysts. The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.03 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.17 and -$0.45 for the fiscal current year, implying an average EPS of -$0.29. EPS for the following year is -$0.21, with 14.0 analysts recommending between -$0.02 and -$0.46.
Revenue Estimates
In the current quarter, 13 analysts expect revenue to total $47.38M. It ranges from a high estimate of $50.8M to a low estimate of $45.2M. As of the current estimate, Maravai LifeSciences Holdings Inc’s year-ago sales were $73.4MFor the next quarter, 13 analysts are estimating revenue of $50M. There is a high estimate of $53.9M for the next quarter, whereas the lowest estimate is $46.73M.
A total of 14 analysts have provided revenue estimates for MRVI’s current fiscal year. The highest revenue estimate was $205M, while the lowest revenue estimate was $185.6M, resulting in an average revenue estimate of $194.36M. In the same quarter a year ago, actual revenue was $259.19MBased on 14 analysts’ estimates, the company’s revenue will be $215.83M in the next fiscal year. The high estimate is $234.17M and the low estimate is $203.49M.
